EKG Quote, Financials, Valuation and Earnings

Range Cancer Therapeutics ETF has a net margin of -- compared to First Trust Nasdaq Lux Digi Health Solutions ETF's net margin of --. First Trust Nasdaq Lux Digi Health Solutions ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.

First Trust Nasdaq Lux Digi Health Solutions ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that First Trust Nasdaq Lux Digi Health Solutions ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe First Trust Nasdaq Lux Digi Health Solutions ETF is more attractive than Range Cancer Therapeutics ETF.

First Trust Nasdaq Lux Digi Health Solutions ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.71%.

First Trust Nasdaq Lux Digi Health Solutions ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. First Trust Nasdaq Lux Digi Health Solutions ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.

First Trust Nasdaq Lux Digi Health Solutions ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. First Trust Nasdaq Lux Digi Health Solutions ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, First Trust Nasdaq Lux Digi Health Solutions ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for First Trust Nasdaq Lux Digi Health Solutions ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.

First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to First Trust Nasdaq Lux Digi Health Solutions ETF's net margin of --. First Trust Nasdaq Lux Digi Health Solutions ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.

First Trust Nasdaq Lux Digi Health Solutions ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that First Trust Nasdaq Lux Digi Health Solutions ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe First Trust Nasdaq Lux Digi Health Solutions ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.

First Trust Nasdaq Lux Digi Health Solutions ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.671, suggesting its less volatile than the S&P 500 by 32.903%.

First Trust Nasdaq Lux Digi Health Solutions ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0.7% to investors and pays a quarterly dividend of $1.17 per share. First Trust Nasdaq Lux Digi Health Solutions ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.

First Trust Nasdaq Lux Digi Health Solutions ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. First Trust Nasdaq Lux Digi Health Solutions ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, First Trust Nasdaq Lux Digi Health Solutions ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for First Trust Nasdaq Lux Digi Health Solutions ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.